Bristol-Myers Squibb
BMY
2,361 hedge funds and large institutions have $103B invested in Bristol-Myers Squibb in 2020 Q4 according to their latest regulatory filings, with 287 funds opening new positions, 950 increasing their positions, 870 reducing their positions, and 107 closing their positions.
168% more first-time investments, than exits
New positions opened: 287 | Existing positions closed: 107
11% more call options, than puts
Call options by funds: $1.59B | Put options by funds: $1.43B
7% more funds holding
Funds holding: 2,214 → 2,361 (+147)
9% more repeat investments, than reductions
Existing positions increased: 950 | Existing positions reduced: 870
3% more capital invested
Capital invested by funds: $100B → $103B (+$2.76B)
0.38% less ownership
Funds ownership: 73.98% → 73.6% (-0.38%)
16% less funds holding in top 10
Funds holding in top 10: 93 → 78 (-15)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$618M |
| 2 |
JP Morgan Chase
New York
|
+$368M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$311M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
+$239M |
| 5 |
Morgan Stanley
New York
|
+$237M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$744M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$507M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$430M |
| 4 |
Two Sigma Advisers
New York
|
-$242M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$215M |
BMY Hedge Fund Activity: Q4 2020 in Review
2,361 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q4 2020, worth a combined $103B — up 2.8% from $100B a quarter earlier.
Buyers outnumbered sellers: 287 funds opened new BMY positions and 107 closed out — a net gain of 180 holders — while 950 added to existing stakes and 870 trimmed.
The largest buyer was BlackRock, adding an estimated $618M. The largest seller was Renaissance Technologies, cutting an estimated $744M.
- 2,361 institutional investors held Bristol-Myers Squibb (BMY) as of Q4 2020, up from 2,214 in Q3 2020.
- Funds reported $103B of Bristol-Myers Squibb stock for Q4 2020, up 2.8% quarter-over-quarter.
- 287 funds opened new Bristol-Myers Squibb positions in Q4 2020 and 107 closed out, a net change of +180 holders.
- The largest Bristol-Myers Squibb buyer in Q4 2020 was BlackRock, an estimated $618M added.
- The largest Bristol-Myers Squibb seller in Q4 2020 was Renaissance Technologies, an estimated $744M sold.
Based on aggregated 13F filings for Q4 2020.